Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis C
100%
Liver Cell Carcinoma
72%
Hepatitis C Virus
60%
Chronic Hepatitis B
60%
Liver Cirrhosis
57%
Ribavirin
55%
Antivirus Agent
48%
Telaprevir
37%
Hepatitis B Virus
33%
Peginterferon
28%
Sofosbuvir
28%
Interferon
25%
Adverse Event
24%
Hepatitis C
24%
Antiviral Drug
23%
Fibrosis
23%
Tolerability
23%
Tenofovir Alafenamide
21%
Antiviral Therapy
21%
Infection
21%
Entecavir
19%
Tenofovir Disoproxil
17%
Viral Clearance
15%
Cohort Study
14%
Chronic Kidney Failure
14%
Catenin
13%
Peginterferon Alpha2b
13%
Hepatitis B
12%
Nonalcoholic Fatty Liver
12%
Liver Disease
12%
Prevalence
10%
Interleukin 28B
10%
Tenofovir
9%
Chronic Hepatitis
9%
Population Study
9%
Recurrent Disease
9%
Ledipasvir Plus Sofosbuvir
9%
Thrombocytopenia
8%
Acquired Immune Deficiency Syndrome
8%
Carotid Atherosclerosis
8%
Diseases
8%
Asunaprevir
8%
Daclatasvir
8%
Elimination
8%
Virus RNA
7%
Biological Marker
7%
Alanine Aminotransferase
7%
Ledipasvir
6%
All Cause Mortality
6%
Hepatitis B(e) Antigen
6%
Medicine and Dentistry
Chronic Hepatitis C
67%
Hepatocellular Carcinoma
63%
Chronic Hepatitis B
61%
Hepatitis C Virus
40%
Liver Cirrhosis
39%
Antiviral Therapy
35%
Ribavirin
30%
Fibrosis
26%
Hepatitis B Virus
26%
Entecavir
24%
Telaprevir
23%
Tenofovir Alafenamide
21%
Chronic Kidney Disease
19%
Antivirus Agent
19%
Peginterferon
18%
Hepatitis C
16%
Antiviral Drug
14%
Hazard Ratio
14%
Tenofovir Disoproxil
14%
Viral Clearance
14%
Sofosbuvir
14%
FibroScan
13%
Cohort Analysis
13%
Glomerular Filtration Rate
12%
Infection
10%
Insulin Resistance
10%
Propensity Score Matching
9%
Anemia
9%
Transient Elastography
9%
Population Research
8%
Kampo
8%
Acquired Immune Deficiency Syndrome
8%
Ethnic Disparity
8%
Chronic Hepatitis
8%
Tenofovir
8%
Odds Ratio
8%
Interleukin 28B
8%
Biological Marker
7%
Interferon
7%
Oral
7%
Hepatitis B
7%
Single Nucleotide Polymorphism
6%
Albumin
6%
Liver Function
6%
Platelet
6%
Human Immunodeficiency Virus
6%
Nucleoside Analog
6%
Focused Ion Beam
6%
Homeostatic Model Assessment
6%
Thrombocytopenia
6%
Immunology and Microbiology
Hepatitis C
74%
Hepatitis B
68%
Hepatitis C Virus
67%
Hepatitis B Virus
38%
Infection
37%
Infectious Disease
36%
Tenofovir
31%
Cirrhosis
27%
Ribavirin
22%
Interferon Type I
21%
Ribonucleic Acid
21%
Viral Clearance
18%
Telaprevir
17%
Human Immunodeficiency Virus
17%
Pretreatment
16%
HBV DNA
14%
Peginterferon Alfa-2b
13%
Sofosbuvir
11%
HBsAg
11%
Hepatitis B Antigen
11%
Hepatitis B(e) Antigen
11%
Glomerulus Filtration
10%
Propensity Score Matching
10%
Prevalence
9%
Ledipasvir
9%
Alanine
8%
Interleukin 28B
8%
Steatohepatitis
8%
Virus Reactivation
8%
Insulin Resistance
8%
Pegylated Interferon
8%
DNA Virus
6%
Single Nucleotide Polymorphism
6%
Sustained Viral Response
6%
Homeostasis
6%
Acquired Immune Deficiency Syndrome
6%
Real Time Polymerase Chain Reaction
6%
Immune Reconstitution Inflammatory Syndrome
5%
Non-Alcoholic Fatty Liver Disease
5%
Hepatitis B Core Antibody
5%
All Cause Mortality
5%
Polyethylene Glycol
5%
Poly(ethylene Glycol)
5%
Human Immunodeficiency Virus Infection
5%
Alpha2b Interferon Plus Ribavirin
5%